A.L. Terekhova

A.L. Terekhova

Auto-generated profile, based on publicly available information

A.L. Terekhova

I.M.Sechenov First Moscow State Medical University, Moscow, Russia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2017 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
IDIvan I. Dedov
Ivan I. Dedov
GMGalina A. Mel'NIchenko
Galina A. Mel'NIchenko
MSMarina Shestakova
Marina Shestakova
RRRoman V. Rozhivanov
Roman V. Rozhivanov
ATAnna L. Terehova
Anna L. Terehova
DKDmitriy G. Kurbatov
Dmitriy G. Kurbatov
Hypogonadism in men, defined as a reduction in serum testosterone in combination with characteristic symptoms and/or signs (described in detail later), is common in diabetes mellitus (DM). These recommendations do not cover the whole range of pathologies that cause the development of testosterone deficiency (hypogonadism), but focus on its clinical variants and characteristic for men with diabetes. The recommendations provide data on the prevalence of hypogonadism in diabetes, its etiology. In the section "diagnostics" the features of anamnesis of patients with hypogonadism with diabetes, the necessary methods of physical and laboratory examination are presented in detail. The risk factors and clinical consequences of hypogonadism are separately examined. In the section "choice of treatment methods", there are possible treatment options for such patients using various androgenic therapies, taking into account the needs of the man, maintaining his reproductive function and risk factors. Particular attention is paid to indications, contraindications and risk factors for androgen therapy in men with diabetes, especially in old age. With this in mind, principles for monitoring the treatment are developed. Based on a large number of studies, favorable effects of androgen replacement therapy in men with hypogonadism and diabetes have been demonstrated.

20 June 2017 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
GMGalina Afanas'EVna Melnichenko
Galina Afanas'EVna Melnichenko
MSMarina Shestakova
Marina Shestakova
RRRoman Viktorovich Rozhivanov
Roman Viktorovich Rozhivanov
ATAnna Leont'EVna Terehova
Anna Leont'EVna Terehova
AZAlexey Vadimovich Zilov
Alexey Vadimovich Zilov
DKDmitriy Gennad'EVich Kurbatov
Dmitriy Gennad'EVich Kurbatov
Hypogonadism in male patients is defined as a decrease in the serum testosterone level; it is associated with specific symptoms and/or signs (see the detailed description below). It is a common complication in diabetes mellitus. The guidelines do not review all disorders leading to the development of hypogonadism but focus on options for the treatment of hypogonadism, which is generally observed in male patients with diabetes. In the literature, data on the prevalence of hypogonadism in patients with diabetes are available. In the section on diagnostics, the medical history of patients with hypogonadism and diabetes, including the necessary methods for physical and laboratory inspection. Risk factors for and the clinical consequences of hypogonadism are separately considered. In the section on treatment options, variations in treatment using various androgenic therapeutic agents based on patients requirements, conservation of their reproductive function, and their risk factors are provided. Special attention is given to indications of, contraindications of and risk factors for androgenic therapy in male patients with diabetes, particularly those in their advanced age. The principles of the clinical monitoring are developed. The favourable effects of androgenic therapy for hypogonadism in male patients with diabetes are shown.

1 January 2023 in Endocrinology: News, Opinions, Training
Verified
Journal Article
Open access
ATA.L. Terekhova
A.L. Terekhova
Ситаглиптин с позиции современной клинической практики

1 January 2024 in Endocrinology: News, Opinions, Training
Verified
Journal Article
Open access
ATA.L. Terekhova
A.L. Terekhova
Ингибиторы дипептидилпептидазы 4-го типа в терапии сахарного диабета 2 типа: что мы знаем сегодня?